5-Amino-1MQ vs PE-22-28
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
5-Amino-1MQCognitive Enhancement
PE-22-28- Summary
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- Half-Life
- Estimated 4–8 hours
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- Admin Route
- Oral
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 50–100 mg
- 200–400 mcg
- Frequency
- Once to twice daily
- Once daily
- Key Benefits
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Side Effects
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Stacks With
- —
- —